Category Archives: Delinkage

Indian Civil Society letter on TB Declaration negotiations -UN High Level Meeting

To, Mr. Narendra Modi, Prime Minister of India Mr. J. P. Nadda, Health Minister Ms. Sushma Swaraj, Foreign Minister Mr. Suresh Prabhu, Commerce Minister Date: 31st July 2018 Sub: Asking India to support TRIPS flexibilities in UN High Level Meeting on TB … Continue reading

Posted in Access to Medecines, Delinkage, R&D, TRIPS, TRIPS flexibilities, Tuberculosis (TB), Uncategorized | Leave a comment

Draft TB declaration: US, EU push against funding, delinkage pledges

Source: POLITICO PRO| June 12, 2018 The EU and U.S. are resisting concrete commitments on new funding for tuberculosis ahead of a high-level U.N. meeting about fighting the world’s top infectious killer. The two regions are also pushing to eliminate language … Continue reading

Posted in Delinkage, Tuberculosis (TB) | Leave a comment

Stakeholder Intervention at 19th RCEP negotiations round- James Love, Knowledge Ecology International

These are the notes I used when providing the KEI comments at the July 25, 2017 civil society stakeholder forum at the 19th round of the RCEP negotiation. My name is James Love. I work for Knowledge Ecology International, an … Continue reading

Posted in Delinkage, FTA, IPR, Patent, R&D, Regional Comprehensive Economic Partnership, TRIPS, TRIPS plus, TRIPS&IP rights, Uncategorized | Leave a comment

Lexmark: The Supreme Court’s patent exhaustion case and parallel trade in drugs

Source: Knowledge Ecology International The Supreme Court’s decision in IMPRESSION PRODUCTS, INC. v. LEXMARK INTERNATIONAL, INC.  has clarified that the United States has world wide exhaustion of patent rights.   According to Professor Fred Abbott, who knows a lot about this issue, and … Continue reading

Posted in Cancer, Delinkage, ISDS, R&D, Uncategorized, USFDA | Leave a comment

Better life through medicine—let’s leave no one behind

Source: http://www.thelancet.com The Lancet Commission on Essential Medicines Policies  rightfully addresses the need to guarantee access to essential medicines for all. However, we cannot achieve any real progress without acknowledging that the current patent-based business model and the way we … Continue reading

Posted in Delinkage, R&D, R&D, Sofosbuvir, TRIPS, TRIPS flexibilities, Uncategorized | Leave a comment

UN High Level Panel report is good prescription for change in access to medicines

Source: PharmaLetter | October 18, 2016 In our weekly expert view piece, Rohit Malpani, director of policy and analysis for Mèdecins Sans Frontiéres Access Campaign, discusses the UN Secretary General’s High-Level Panel report on Access to Medicines and looks at the … Continue reading

Posted in Delinkage, R&D, TPP, TRIPS, TRIPS flexibilities, TRIPS plus, Uncategorized | Leave a comment

Pay big pharma to solve antibiotics crisis, says UK government review

The Guardian; Pharmaceutical companies should be given cash incentives of up to $3bn to find and develop new antibiotics desperately needed to keep infections at bay, according to a UK government review. Jim O’Neill, the economist and former chair of … Continue reading

Posted in Antibiotics, Delinkage, Innovation | Leave a comment